Literature DB >> 26427659

Deregulation of miR-93 and miR-143 in human esophageal cancer.

Mohammad Hossein Ansari1, Shiva Irani2, Houri Edalat1, Ruhul Amin3, Amaneh Mohammadi Roushandeh4,5.   

Abstract

Esophageal squamous cell carcinoma (ESCC) is the second and third most common malignancy in Iranian males and females, respectively. Treatment of ESCC is largely ineffective due to lack of detection at early stages of the disease. In recent years, miRNA, a small RNA molecule, has drawn much attention to researchers as a potential biomarker for esophageal cancer. miR-93 and miR-143 are two miRNA molecules reported to be frequently deregulated in various cancers, including prostate, stomach, cervix, and etc. The purpose of this study was to investigate the expression levels of these miRNAs and evaluate their diagnostic and therapeutic potential in esophageal squamous cell carcinoma. In this study, total RNA was extracted from 30 tumor tissues and 30 nontumor tissues of esophageal tumor margins, using RNX-plus solution. After validating the quality and quantity of total RNA, cDNAs of interest were synthesized using microRNA-specific cDNA Synthesis Kit. The expression level of miR-93 and miR-143 was evaluated using quantitative real-time PCR with miRNA-specific primers. Finally, the obtained data was analyzed by SPSS ver.20 software and paired t test was performed to observe the significance of difference between groups. The expression level of miR-93 was significantly increased and of miR-143 was significantly decreased in most of the examined tumor tissues, compared to nontumor tissues. Also, our findings did not detect correlation between mir-93 and mir-143 expressions in regard to stage and grade of the samples. These findings suggest that the deregulation of these miRNAs may play an important role in esophageal squamous cell carcinoma. Both miR-93 and miR-143 might be used as potential biomarkers in esophageal squamous cell carcinoma. However, more studies with large population of samples are necessary.

Entities:  

Keywords:  Adenocarcinoma of the esophagus; Esophageal cancer; Squamous cell carcinoma; miR-143; miR-93

Mesh:

Substances:

Year:  2015        PMID: 26427659     DOI: 10.1007/s13277-015-3987-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  66 in total

Review 1.  MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.

Authors:  William C S Cho
Journal:  Int J Biochem Cell Biol       Date:  2009-12-22       Impact factor: 5.085

Review 2.  Gene silencing in vitro and in vivo using intronic microRNAs.

Authors:  Shi-Lung Lin; Shao-Yao Ying
Journal:  Methods Mol Biol       Date:  2006

Review 3.  Functional significance of aberrantly expressed microRNAs in prostate cancer.

Authors:  Yusuke Goto; Akira Kurozumi; Hideki Enokida; Tomohiko Ichikawa; Naohiko Seki
Journal:  Int J Urol       Date:  2015-01-20       Impact factor: 3.369

4.  Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor.

Authors:  Fengjun Wang; Zhiguo Zheng; Jiangfeng Guo; Xianfeng Ding
Journal:  Gynecol Oncol       Date:  2010-12       Impact factor: 5.482

5.  The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer.

Authors:  Satoko Kojima; Hideki Enokida; Hirofumi Yoshino; Toshihiko Itesako; Takeshi Chiyomaru; Takashi Kinoshita; Miki Fuse; Rika Nishikawa; Yusuke Goto; Yukio Naya; Masayuki Nakagawa; Naohiko Seki
Journal:  J Hum Genet       Date:  2013-11-28       Impact factor: 3.172

6.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers.

Authors:  George Adrian Calin; Cinzia Sevignani; Calin Dan Dumitru; Terry Hyslop; Evan Noch; Sai Yendamuri; Masayoshi Shimizu; Sashi Rattan; Florencia Bullrich; Massimo Negrini; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-18       Impact factor: 11.205

7.  MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus.

Authors:  Dipen M Maru; Rajesh R Singh; Christina Hannah; Constance T Albarracin; Yong X Li; Ronald Abraham; Angela M Romans; Hui Yao; Madan G Luthra; Sharmila Anandasabapathy; Stephen G Swisher; Wayne L Hofstetter; Asif Rashid; Rajyalakshmi Luthra
Journal:  Am J Pathol       Date:  2009-03-26       Impact factor: 4.307

8.  Functional integration of microRNAs into oncogenic and tumor suppressor pathways.

Authors:  Craig D Lotterman; Oliver A Kent; Joshua T Mendell
Journal:  Cell Cycle       Date:  2008-08-17       Impact factor: 4.534

9.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies.

Authors:  Michael D Mattie; Christopher C Benz; Jessica Bowers; Kelly Sensinger; Linda Wong; Gary K Scott; Vita Fedele; David Ginzinger; Robert Getts; Chris Haqq
Journal:  Mol Cancer       Date:  2006-06-19       Impact factor: 27.401

10.  miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.

Authors:  Cyrielle Clapé; Vanessa Fritz; Corinne Henriquet; Florence Apparailly; Pedro Luis Fernandez; François Iborra; Christophe Avancès; Martin Villalba; Stéphane Culine; Lluis Fajas
Journal:  PLoS One       Date:  2009-10-26       Impact factor: 3.240

View more
  20 in total

1.  Knockdown of UCHL3 inhibits esophageal squamous cell carcinoma progression by reducing CRY2 methylation.

Authors:  Jijun Xue; Jinyuan Yi; Xiaolong Zhu
Journal:  Hum Cell       Date:  2022-01-28       Impact factor: 4.174

Review 2.  The Role and Interactions of Programmed Cell Death 4 and its Regulation by microRNA in Transformed Cells of the Gastrointestinal Tract.

Authors:  William Frank Ferris
Journal:  Front Oncol       Date:  2022-06-29       Impact factor: 5.738

3.  MicroRNA-93 promotes cell proliferation by directly targeting P21 in osteosarcoma cells.

Authors:  Yu He; Bo Yu
Journal:  Exp Ther Med       Date:  2017-03-08       Impact factor: 2.447

4.  Direct Downregulation of B-Cell Translocation Gene 3 by microRNA-93 Is Required for Desensitizing Esophageal Cancer to Radiotherapy.

Authors:  Hujun Cui; Shengqiang Zhang; Hongbo Zhou; Ling Guo
Journal:  Dig Dis Sci       Date:  2017-04-22       Impact factor: 3.199

5.  ELK1 activated-long noncoding RNA LBX2-AS1 aggravates the progression of ovarian cancer through targeting miR-4784/KDM5C axis.

Authors:  Hangzhi Gu; Rongrong Lin; Feiyun Zheng; Qian Zhang
Journal:  J Mol Histol       Date:  2020-10-24       Impact factor: 2.611

6.  Pemetrexed plus dendritic cells as third-line therapy for metastatic esophageal squamous cell carcinoma.

Authors:  Bin Zhang; Rui Li; Chun-Xiao Chang; Yong Han; Sheng-Bin Shi; Jing Tian
Journal:  Onco Targets Ther       Date:  2016-06-29       Impact factor: 4.147

7.  Identification of molecular targets for esophageal carcinoma diagnosis using miRNA-seq and RNA-seq data from The Cancer Genome Atlas: a study of 187 cases.

Authors:  Jiang-Hui Zeng; Dan-Dan Xiong; Yu-Yan Pang; Yu Zhang; Rui-Xue Tang; Dian-Zhong Luo; Gang Chen
Journal:  Oncotarget       Date:  2017-05-30

8.  PTENP1 inhibits the growth of esophageal squamous cell carcinoma by regulating SOCS6 expression and correlates with disease prognosis.

Authors:  Tuotuo Gong; Shuyu Zheng; Shan Huang; Shenbo Fu; Xuanwei Zhang; Shupei Pan; Tian Yang; Yuchen Sun; Ya Wang; Beina Hui; Jia Guo; Xiaozhi Zhang
Journal:  Mol Carcinog       Date:  2017-08-21       Impact factor: 4.784

Review 9.  Flaming the fight against cancer cells: the role of microRNA-93.

Authors:  Milad Ashrafizadeh; Masoud Najafi; Reza Mohammadinejad; Tahereh Farkhondeh; Saeed Samarghandian
Journal:  Cancer Cell Int       Date:  2020-06-29       Impact factor: 5.722

Review 10.  Research progress on the relationship between zinc deficiency, related microRNAs, and esophageal carcinoma.

Authors:  Cong-Min Liu; Di Liang; Jing Jin; Dao-Juan Li; Ya-Chen Zhang; Zhao-Yu Gao; Yu-Tong He
Journal:  Thorac Cancer       Date:  2017-09-11       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.